ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

18 Dec 2024 04:00:41 By Nasdaq GlobeNewswire

Esperion Announces $210 Million Convertible Debt Financing

13 Dec 2024 03:00:00 By Nasdaq GlobeNewswire

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

12 Dec 2024 05:00:55 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ESPERION THERAPEUTICS INC. - COMMON STOCK

09 Dec 2024 11:32:19 By NetDania Notify

NetDania - New 12 months High: ESPERION THERAPEUTICS INC. - COMMON STOCK

04 Dec 2024 06:47:22 By NetDania Notify

NetDania - New 12 months High: ESPERION THERAPEUTICS INC. - COMMON STOCK

02 Dec 2024 09:47:28 By NetDania Notify

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

02 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

26 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

21 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

18 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 Nov 2024 13:15:00 By Nasdaq GlobeNewswire

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

07 Nov 2024 03:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

04 Nov 2024 05:00:25 By Nasdaq GlobeNewswire

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

31 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion to Report Third Quarter 2024 Financial Results on November 7

24 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

02 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

25 Sep 2024 13:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

05 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

03 Sep 2024 05:00:00 By Nasdaq GlobeNewswire